Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02772965 · ClinicalTrials.gov registry record · Phase 3
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
A Phase 3 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
NCT02772965 is a Phase 3 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 306 participants.
The verdict
NCT02772965, a Phase 3 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone in inducing and maintaining steroid-free remission for children with Crohn's Disease.
Interventions
- DRUG Methotrexate
- OTHER Sugar pill (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2016-10 |
| Est. Completion | 2022-04-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02772965
The ClinicalTrials.gov registry entry for NCT02772965 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT02772965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02772965 about?
NCT02772965 is a clinical study titled "Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy". The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone in inducing and maintaining steroid-free remission for children with Crohn's Disease.
What is the current status of trial NCT02772965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 2016-10. Estimated completion is 2022-04-07.
What interventions are being tested in trial NCT02772965?
The interventions under investigation include: Methotrexate (DRUG), Sugar pill (placebo) (OTHER).
Who is sponsoring clinical trial NCT02772965?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.